Trial Profile
A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Depo-Provera (Medroxyprogesterone Acetate) (NSC #26386) Compared to Depo-Provera Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 17 Nov 2021
Price :
$35
*
At a glance
- Drugs Entinostat (Primary) ; Medroxyprogesterone
- Indications Adenocarcinoma; Endometrial cancer
- Focus Therapeutic Use
- Acronyms Surgical Window
- 05 May 2021 Status changed from active, no longer recruiting to completed.
- 25 Mar 2021 Primary endpoint (Mean post-treatment tumor progesterone receptor score) has not been met as per results published in the Clinical Cancer Research
- 25 Mar 2021 Results published in the Clinical Cancer Research